Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news

Show

From To
Panel: Compulsory licensing could address high-priced medicines in Europe

The high prices of medicine, which affects access to affordable medicine, was a theme of the annual World Health Assembly over the past week. In one side event, a panel discussed compulsory licensing as a vehicle to be used in combatting the high prices of medicine, not only in developing countries, but in Europe.

Published
29 May 2015
From
Intellectual Property Watch
Consumers Sue Anthem for Denying Coverage for a Hepatitis C Drug

The controversy over the new crop of hepatitis C treatments has taken yet another turn as consumers are starting to file lawsuits against insurers that deny them access to the medicines. Over the past two weeks, two different women alleged that Anthem Blue Cross refused to pay for the Harvoni treatment sold by Gilead Sciences because it was not deemed “medically necessary.”

Published
28 May 2015
From
Wall Street Journal
NHS England accused of interference over hepatitis C drug

Officials at NHS England have been accused of interfering in a process to decide whether a drug which can cure Hepatitis C should be made available to patients on the health service.

Published
26 May 2015
From
Channel 4 News
Hepatitis C treatment for people in prison may be highly cost-effective in England

Reducing the duration of direct-acting antiviral treatment for hepatitis C will make treatment for people in prison in England highly cost-effective, and could provide an important opportunity

Published
21 May 2015
By
Keith Alcorn
Hepatitis B and C - An Action Plan for Saving Lives in Europe

Last year, leading experts, institutions, patient organisations and pharmaceutical industry representatives met and agreed that the major recommendations produced between 2011 and 2014 should be compiled into one comprehensive document, to make it easier for policy makers, decision makers, civil society organisations and healthcare institutions to tackle viral hepatitis effectively.

Published
20 May 2015
From
European Liver Patients Association
Pricing remains main barrier to HCV eradication

Eradication is technically feasible, Dr. Edlin said during a Monday morning AASLD Clinical Symposium, but not likely until current pricing policies change.

Published
20 May 2015
From
Digestive Disease Week News
Is Gilead Sciences Its Own Worst Enemy?

Gilead's science is so good that it's actually destroying the company's business. Pharma companies, like most other businesses, make the bulk of their money through repeat business. Gilead, however, is doing something really no other drugmaker is doing -- namely curing patients of devastating infectious diseases.

Published
20 May 2015
From
Motley Fool
Statin use associated with lower risk of liver decompensation and death in hepatitis C patients with cirrhosis

People with hepatitis and liver cirrhosis were significantly less likely to progress to decompensated disease and less likely to die if they used statins to control blood

Published
19 May 2015
By
Liz Highleyman
Investing in hepatitis C drugs could save the economy billions, researchers suggest

Researchers who examined the effect of treating hepatitis C patients with the newer generation of oral drugs suggest while these medications may cost tens of thousands of dollars for a 12-week course, they could avert billions in lost productivity.

Published
19 May 2015
From
Medical News Today
Civacir immune globulin may help prevent HCV reinfection after liver transplant

Civacir, a hepatitis C immune globulin or antibody product, reduced the likelihood of hepatitis C virus infecting the new liver graft after transplantation in people who were

Published
17 May 2015
By
Liz Highleyman
← First12345...58Next →

Filter by country